Key result
Systemic serial administration of doxorubicin caused significant myocardial changes after the first course, whereas a single intravesical instillation did not cause laboratory or instrumental changes.
Why the study?
The toxic effects of intravenous doxorubicin on vital organs including the heart require further research, prompting an evaluation of cardiotoxicity manifestations and progression in patients with bladder cancer receiving systemic versus intravesical doxorubicin.
Does systemic versus intravesical doxorubicin administration cause cardiotoxicity in patients with bladder cancer?
Cohort (n=96)
Does systemic versus intravesical doxorubicin administration cause cardiotoxicity in patients with bladder cancer?
Systemic doxorubicin induces early signs of cardiotoxicity in bladder cancer patients, whereas intravesical administration appears safe from a cardiac perspective.
Answers are grounded in this paper and cite their sources.
Doxorubicin cardiotoxicity in bladder cancer warrants caution; level 5 evidence leaves open need for larger studies.
Due to the constant increase in morbidity and mortality, bladder cancer remains a pressing problem in modern medicine. Despite the success of chemotherapy, chemotherapy physicians around the world have been concerned about the safety of these drugs for many years. Doxorubicin has been used as an antitumor drug for more than 40 years in various hematological and solid malignancies, however, its toxic effects when administered intravenously to vital organs and organ systems, including the heart, require further research. The aim of our study was to evaluate the manifestations and progression of cardiotoxicity in patients with bladder cancer with systemic and intravesical administration of doxorubicin. The study included 96 patients who were divided into three groups: the first group or the control group – patients who had a confirmed diagnosis of first stage bladder cancer, were treated surgically and did not receive doxorubicin; the second group – patients who, in addition to surgical treatment, received doxorubicin systemically (intravenously) in a therapeutic dose; the third group – patients who received doxorubicin at a dose of 50 mg, locally, by instillation of the drug into the bladder cavity, after prior catheterization with an elastic catheter. ECG data and biochemical markers of myocardial destruction before and after chemotherapy were studied. The study found that systemic serial administration of doxorubicin to patients with bladder cancer causes significant changes in the myocardium after the first course of chemotherapy. A single intravesical instillation of doxorubicin does not cause changes in laboratory and instrumental heart rate.
No takes yet. Share an insight, caveat, or question.
N. L. Hodovan (2021) conducted a cohort in Bladder cancer (n=96). Doxorubicin (systemic or intravesical) vs. Surgical treatment only (no doxorubicin) was evaluated on ECG data and biochemical markers of myocardial destruction. Systemic serial administration of doxorubicin caused significant myocardial changes after the first course, whereas a single intravesical instillation did not cause laboratory or instrumental changes.
Synapse has enriched 10 related papers. Consider them for comparative context: